stockrow
Saturday 7 November 2026
Export NUVB’s income statement to Excel — free account
Nuvation Bio Inc.
NUVB Healthcare Biotechnology
Nuvation Bio Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.9 million, up 699.0% from fiscal 2024.
- Revenue
- +242.6%
- EPS
- +25.6%
- Free cash flow
- +34.1%
- Total debt
- +441.5%
Quarter to September 2026, against a year earlier
4.17
0.02
−0.48%
Follow NUVB
Alert me
Nuvation Bio Inc. (NUVB) P/E ratio
Nuvation Bio Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 6 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| IMCR Immunocore Holdings PLC Sponsored ADR compare | n/m |
| TYRA Tyra Biosciences, Inc. compare | n/m |
| NUVB Nuvation Bio Inc. | n/m |
| QURE uniQure N.V. compare | n/m |
| RARE Ultragenyx Pharmaceutical Inc. compare | n/m |
| NBTX Nanobiotix S.A. - Sponsored ADR compare | n/m |
| PGEN Precigen, Inc. compare | 60.3× |
| AAPG Ascentage Pharma Group International - Unsponsored ADR compare | — |
| ADRX ADARx Pharmaceuticals, Inc. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)